Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Imugene ( (AU:IMU) ) has provided an announcement.
Imugene Limited has issued 1,736,111 fully paid ordinary shares to CVI Investment Inc. following the conversion of five zero-coupon convertible notes, expanding its share capital without undertaking a separate disclosure to investors. The company confirmed it remains compliant with its financial reporting and continuous disclosure obligations under the Corporations Act and stated there is no excluded information that must be disclosed, signalling routine capital management with no undisclosed material developments for shareholders.
The most recent analyst rating on (AU:IMU) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Imugene stock, see the AU:IMU Stock Forecast page.
More about Imugene
Imugene Limited is a clinical-stage immuno-oncology company developing novel immunotherapies that activate the immune system to treat and eradicate cancers. Its pipeline includes the off-the-shelf allogeneic CAR T cell therapy azer-cel targeting CD19 for blood cancers, as well as the CF33 oncolytic virotherapy platform aimed at a variety of solid and liquid tumours in combination with standard of care and emerging immunotherapies. Supported by an international team of cancer experts, Imugene seeks to establish its therapies as foundation treatments in the rapidly growing global cancer immunotherapy market.
Average Trading Volume: 1,859,614
Technical Sentiment Signal: Sell
Current Market Cap: A$96.19M
For an in-depth examination of IMU stock, go to TipRanks’ Overview page.